Global HIV-1 Integrase (EC 2.7.7.) Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016" report to their offering.

The report 'HIV-1 Integrase - Pipeline Review, H1 2016' outlays comprehensive information on the HIV-1 Integrase (EC 2.7.7.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

'HIV-1 Integrase - Pipeline Review, H1 2016'; HIV-1 Integrase (EC 2.7.7.) pipeline Target constitutes close to 13 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; HIV-1 Integrase (EC 2.7.7.) HIV-1 integrase is a viral protein that catalyzes the first two steps of the three-step DNA integration process and belongs to the superfamily of polynucleotidyl transferases. The integration of HIV-1 DNA into the host chromosome is achieved by the integrase protein performing a series of DNA cleaving and ligation reactions.

It also reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. HIV-1 Integrase Overview
  3. Therapeutics Development
  4. Pipeline Products for HIV-1 Integrase - Overview
  5. Pipeline Products for HIV-1 Integrase - Comparative Analysis
  6. HIV-1 Integrase - Therapeutics under Development by Companies
  7. HIV-1 Integrase - Therapeutics under Investigation by Universities/Institutes
  8. HIV-1 Integrase Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. HIV-1 Integrase - Products under Development by Companies
  13. HIV-1 Integrase - Products under Investigation by Universities/Institutes
  14. HIV-1 Integrase - Companies Involved in Therapeutics Development
  • Critical Outcome Technologies Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • TGV-Laboratories
  • ViiV Healthcare Limited

For more information about this report visit http://www.researchandmarkets.com/research/ndts7p/hiv1_integrase

Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, HIV/AIDS Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716